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Abstract
Background: The World Health Organization has endorsed the use of molecular methods for the detection of TB
and drug-resistant TB as a rapid alternative to culture-based systems. In South Africa, the Xpert MTB/Rif assay and
the GenoType MTBDRplus have been implemented into reference laboratories for diagnosis of TB and drug-resistan-
ce, but their costs have not been fully elucidated.
Methods: We conducted a detailed reference laboratory cost analysis of new rapid molecular assays (Xpert and
MTBDRplus) for tuberculosis testing and drug-resistance testing in South Africa, and compared with the costs of
conventional approaches involving sputum microscopy, liquid mycobacterial culture, and phenotypic drug
sensitivity testing.
Results: From a laboratory perspective, Xpert MTB/RIF cost $14.93/sample and the MTBDRplus line probe assay cost
$23.46/sample, compared to $16.88/sample using conventional automated liquid culture-based methods.
Laboratory costs of Xpert and MTBDRplus were most influenced by cost of consumables (60-80%).
Conclusions: At current public sector pricing, Xpert MTB/RIF and MTBDRplus are comparable in cost to
mycobacterial culture and conventional drug sensitivity testing. Overall, reference laboratories must balance costs
with performance characteristics and the need for rapid results.
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Background
Currently, less than 10% of multi-drug resistant tubercu-
losis (MDR-TB) cases in the world are detected [1].
Performance of drug susceptibility testing (DST) using
conventional methods relies on solid or liquid media
and is slow and resource intensive. Recently, the World
Health Organization endorsed the use of molecular
methods for the detection of TB and drug-resistvant TB
as a rapid alternative to culture-based systems [2,3].
Two commercially available molecular assays using dif-
ferent methodologies have been implemented in South
Africa -- the GenoType MTBDRplus (‘MTBDRplus,’
Hain Lifescience, Nehren, Germany) and the Xpert
MTB/RIF (‘Xpert,’ Cepheid, Sunnyvale, CA).
MTBDRplus is a line probe assay that has shown good
diagnostic accuracy for the detection of M. tuberculosis in
smear-positive cases and isoniazid and/or rifampin resist-
ance in several validation studies, and test results can be
available in as few as 1–2 days [4-6]. Xpert is an integrated
specimen processing and nucleic acid amplification-based
test for detection of M. tuberculosis and rifampin resist-
ance and offers results within hours. Xpert has the
advantage of high sensitivity when performed on smear
microscopy-positive sputum samples and requires little la-
boratory processing, overhead, or labor [7].
South Africa is a middle-income country that has
sought to scale-up laboratory services to implement
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these new tests. However, while Xpert and MTBDRplus
offer rapid results and similar performance characteris-
tics, each has limitations and neither may be a complete
replacement for conventional culture and DST [2,3,6,7].
Both tests have reduced sensitivity for smear-negative
samples, and conventional DST is needed for expanded
drug resistance testing. MTBDRplus is a technically
complicated assay requiring substantial laboratory re-
sources, and both tests require expensive equipment and
reagents. In August 2012, however, public sector prices
for Xpert consumables were significantly reduced [8]. To
date, little data is available to compare the costs and re-
source needs of these emerging rapid diagnostics to
guide policy-makers and laboratory managers. To ad-
dress this knowledge gap, we performed a detailed cost-
analysis from a laboratory perspective and compared the
costs associated with conventional liquid culture and
DST, MTBDRplus and Xpert. We further explored the
costs of incorporating these assays as stand-alone tests
for TB diagnosis, or alternatively in conjunction with
existing diagnostics.
Methods
Costs associated with mycobacterial testing were ana-
lyzed from a laboratory perspective at the National
Health Laboratory Services (NHLS) National TB Refer-
ence Laboratory in Johannesburg, South Africa. Costs
were collected for testing conducted using Xpert,
MTBDRplus, Ziehl-Neelsen smear microscopy using a
light microscope, and florescence smear microscopy
using auramine-O staining and a light emitting diode
microscope [9]. Costs were also collected for sputum
processing (i.e. digestion and decontamination) using N-
acetyl-L-cysteine-NaOH and concentration by centrifu-
gation [10], liquid culture using the automated BACTEC
MGIT 960 system (BD Diagnostic Systems, Sparks, MD,
USA), indirect phenotypic DST using the MGIT SIRE
system (BD Diagnostic Systems), and anti-MPB64
monoclonal antibody-based species identification
(Capilia TB-Neo, TAUNS Laboratories, Numazu, Japan)
of positive cultures. For the liquid culture testing sce-
nario, all samples were considered to require sputum
processing and MGIT culture; positive cultures were
tested by Ziehl Neelsen smear microscopy to assess for
mycobacteria; cultures positive for mycobacteria were
tested by the anti-MPB64 assay to distinguish M. tuber-
culosis from non-tuberculous mycobacteria, and cultures
positive for M. tuberculosis were subjected to phenotypic
MGIT SIRE DST. Xpert testing was conducted per
manufacturer instructions and performed using a
4-module GeneXpert (Cepheid) instrument with auto-
mated readout. MTBDRplus was performed according
to manufacturer instructions and consisted of DNA ex-
traction, amplification, and hybridization steps, with
hybridization performed using a GT Blot instrument
(Hain Lifescience).
Costs were analyzed using an “ingredients” approach
that involved multiplying the quantity of inputs used by
their unit prices; costs and wages were gathered using
detailed laboratory records. The amount of staff time,
consumable supplies and equipment quantities utilized
for each test were determined through direct observa-
tion of testing procedures, and included costs associated
with quality assurance and quality control. Overhead la-
boratory costs included indirect labor costs, office and
lab supplies and furniture, general operations costs, and
physical infrastructure costs (i.e. building, utilities, and
maintenance costs). Overhead costs were allocated based
on the volume of testing and amount of physical infra-
structure utilized by each diagnostic system. Equipment
costs were annualized over their useful lifespans. South
Africa is eligible to pay prices negotiated by the Founda-
tion for Innovative Diagnostics (FIND), and costs for
consumables and equipment reflect this pricing struc-
ture [8,11,12]. Laboratory testing capacity was estimated
based on the laboratory operating for 12 hours per day.
Ten percent of all sputum samples were estimated to be
smear-positive and 5% of cultures were estimated to be
positive for M. tuberculosis based on laboratory records.
Unit costs of key equipment and consumables are shown
in Table 1. We evaluated the costs of each diagnostic
system individually and in combination with each other.
All costs are presented in 2012 US dollars.
Results
Base-case laboratory costs for TB diagnostics are shown
in Table 2. Costs per test conducted were $14.93 for
Xpert, $23.46 for MTBDRplus, $3.40 for fluorescence
smear microscopy, $2.25 for Ziehl-Neelson light micros-
copy, $12.16 for MGIT culture, and $26.19 for DST
using MGIT SIRE. We calculated a total cost of $16.88
per specimen tested for the combination of fluorescence
smear microscopy plus the liquid culture testing sce-
nario (sputum processing and MGIT culture, followed
by Ziehl Neelsen smear microscopy on positive cultures,
anti-MPB64 assays on cultures with mycobacterial
growth, and MGIT SIRE DST on cultures with growth
of M. tuberculosis). This combination of fluorescence
microscopy plus the liquid culture testing scenario was
over $6 cheaper per sample than using MTBDRplus on
all sputa, but was more expensive than Xpert (Table 3).
The cost of Xpert was largely attributable to consum-
ables ($11.97 per test [80% of total]), and was driven by
the cost of Xpert cartridges ($9.98 per cartridge, Tables 1
and 2). Alternatively, countries not eligible for FIND-
negotiated discounts may pay up to $78,200 for purchase
of the GeneXpert instrument and $71.63 per cartridge
[8,13]. In the latter scenario, Xpert costs may rise to
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$78.94 per sample and would be substantially more
expensive than conventional diagnostics. Labor costs
associated with performing Xpert were low ($1.13 per
test) compared to MGIT culture ($2.17 per test) or
MTBDRplus($3.46 per test). Overall, if the volume of
testing in the laboratory were reduced by 50%, the cost
of Xpert would rise to $16.50 per test.
By comparison, MTBDRplus costs were similarly at-
tributable largely to consumables ($14.13 per test [60%]),
but also had high labor costs ($3.46 per test) and
overhead costs ($4.28 per test) due to the time involved
and extensive laboratory facilities needed for test
performance.
Laboratory costs associated with alternative diagnostic
algorithms incorporating multiple tests are shown in
Table 3. An intensive TB diagnostic strategy involving
performance of Xpert or MTBDRplus in addition to the
liquid culture testing scenario on all sputum samples
would nearly double laboratory costs per sample ($28.41
and $36.94 per sample for addition of Xpert and
addition of MTBDRplus, respectively) compared to a
strategy of using only the liquid culture testing scenario
(Table 3).
A more selective strategy considered by some labora-
tories to reduce costs might be to perform smear mi-
croscopy plus the liquid culture testing scenario on all
sputum samples to ensure highest diagnostic sensitivity,
but employ molecular testing only selectively for smear
microscopy-positive samples (for MTB confirmation and
rapid drug-resistance results). This strategy would lead
to an incremental cost of less than $3 per sample, com-
pared to using smear microscopy plus the liquid culture
testing scenario (Table 3), while likely substantially redu-
cing the time to diagnosis of resistance.
An additional strategy considered by some labs may be
to utilize molecular assays primarily as a replacement for
conventional DST. Such a strategy would cost $16.51 if
Xpert were used in place of DST (incremental -$0.37
compared to liquid culture scenario with conventional
DST) and $17.75 if MTBDRplus were used in place of
DST (incremental $0.87 compared to liquid culture sce-
nario with conventional DST).
In South Africa, recent guidelines suggest using
GeneXpert for all high risk patients and to additionally
perform conventional culture and DST for confirmation
of positive molecular test results [14]. Such a strategy
would cost $16.86 per TB suspect using GeneXpert as
the molecular assay and $25.39 if MTBDRplus were used
(Table 3).
Discussion
Scale-up of laboratory capacity for detection of TB and
drug resistance is urgently needed, but may be costly.
Current reference standard approaches involving myco-
bacterial culture and DST are slow, and are resource in-
tensive for laboratories to perform. The Xpert MTB/Rif
and MTBDRplus are two WHO recommended plat-
forms for rapid detection of TB and drug-resistant TB
and many low and middle-income countries qualify for
negotiated discounts on these assays [8]. Previously,
there has been limited cost information from a labora-
tory perspective to guide TB control programs and
laboratories in implementing these tests. Our results
suggest that with recent reductions in the price of Xpert
Table 1 Unit costs of key consumables and equipment*
Consumables Unit (quantity) Unit cost $US
NALC/NAOH Kit per Sample $1.73
N95 Mask per Box(100) $55.19
ZN stain per liter $4.87
Auramine-O per liter $4.67
Methylene blue per liter $3.26
Potassium permanganate Per liter $3.22
AFB fixative per 100 ml $8.52
PANTA one box(100) $89.07
MGIT growth supplement one box(100) $70.80
Anti-MPB64 Capilia TB Neo per test $1.69
MGIT Tube per Box(100) $195.00
SIRE kit per kit (35) $127.50
MTBDR rif kit per kit (96) $917.42
Xpert MTB/Rif cartridge per cartridge $9.98
Equipment
Centrifuge plus accessories per Instrument $22,439
Vortex per Instrument $304
Biosafety cabinet per Instrument $3,190
Biosafety cabinet filter replacement yearly $1,608
Biosafety cabinet decontamination q 6months $156
Light microscope per Instrument $3,409
LED microscope per Instrument $4580
Bactec MGIT 960 per Instrument $38,950.00
Epicenter software – $12,500.00
Barcode scanner per Instrument $158.30
Thermocycler per Instrument $5,621.18
Ultrasonicator per Instrument $1,596.42
GTBLOT maintenance semi-annual $487.08
GT BLOT per Instrument $17,557.40
UPS (power supply) per Instrument $137.24
Xpert instrument per Instrument $17,000.00
Xpert calibration per 1800 runs $1,800.00
*Not all items are shown. Additional minor consumables and equipment costs
included but were not limited to costs associated with gloves, disposable
gowns, pipettes and pipetters and tips, computers and supplies, soap and
disinfectant, waste disposal including biohazard bags, microscopy slides, and
other common microbiology supplies.
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Table 2 Component costs for each tuberculosis diagnostic test
Consumables cost per test, in $
(% of total) [uncertainty range]†
Equipment cost per test, in $
(% of total) [ uncertainty range]†
Labor * cost per test, in $
(% of total) [uncertainty range]†
Overhead cost per test, in $
(% of total) [uncertainty range]†
Total cost per test, in $
[uncertainty range]†
Fluorescence smear
microscopy
$0.36 (10%) [$0.27–$0.45] $0.12 (4%) [$0.09–$0.48] $2.18 (64%) [$1.64–$3.00] $0.74 (22%) [$0.18–$0.93] $3.40 [$2.19–$4.76]
Ziehl-Neelsen light
smear microscopy
$0.34 (15%) [$0.26–$0.43] $0.11 (5%) [$0.08–$0.45] $1.05 (47%) [$0.88–$1.53] $0.74 (33%) [$0.18–$0.93] $2.25 [$1.40–$3.24]
MGIT culture $8.05 (66%) [$6.04–$8.65] $1.05 (9%) [$0.71–$4.74] $2.17 (18%) [$2.05–$2.50] $0.89 (7%) [$0.66–$1.11] $12.16 [$9.46–$16.99]
Phenotypic DST
using MGIT SIRE
system
$16.22 (61%) [$12.16–$18.71] $2.77 (10%) [$2.08–$13.42] $4.15 (16%) [$3.41–$6.16] $3.26 (12%) [$2.45–$4.07] $26.39 [$20.10–$42.37]
MTBDRplus $14.13 (60%)[$10.37–$17.24] $1.60 (7%) [$4.17–$7.39] $3.46 (15%) [$2.85–$5.13] $4.28 (18%) [$3.21–$5.35] $23.46[$20.61–$35.12]
Xpert MTB/RIF $11.97 (80%) [$11.49–$19.47] $0.93 (6%) [$0.70–$3.99] $1.13 (8%) [$0.94–$4.30] $0.90 (6%) [$0.22–$1.12] $14.93 [$13.36–$28.88]
Abbreviations: MGIT Mycobacterial Growth Indicator 960 automated liquid culture system, DST Drug Susceptibility Testing using MGIT SIRE system.
*Average salary for laboratory technician was $9.07 per hour based on laboratory records. Range of wages from $7.43 to $16.16 were used for sensitivity analysis based on wages of different skill levels of
laboratory workers.
†Uncertainty range is based on lowest and highest estimates of consumable and equipment components along with range of laboratory volume of testing [e.g. batch size of Xpert testing was varied from 1 sample to
4 samples per run], along with range of salaries for laboratory technicians, and highest and lowest estimates for laboratory overhead.
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cartridges, the cost of Xpert testing is comparable to
that of conventional diagnostics, making it possible to
consider replacement of sputum microscopy and culture
with Xpert from a laboratory cost standpoint. We found
that the cost of Xpert testing ($14.93) in a reference
laboratory in South Africa was similar to performing
the current reference standard of smear-microscopy
followed by liquid culture and conventional DST
($16.88); MTBDRplus was found to be the most costly
($23.46) but offers the benefit of rapid isoniazid resist-
ance testing in addition to rifampin resistance testing.
Costs of molecular testing were most influenced by con-
sumable costs which accounted for 60-80% of total costs
associated with Xpert and MRTBDplus. Xpert addition-
ally offers the benefit of reduced staff time needed for
testing, with potential to increase volume of testing or
increased opportunities and time to perform other diag-
nostic tests or laboratory activities.
Overall, laboratories and TB control programs must
balance costs with performance characteristics and the
need for rapid results [15]. Both molecular tests assessed
in this study offered rapid detection of M. tuberculosis
and drug-resistance. However, reliance on either Xpert
or MTBDRplus alone for diagnosis of TB and drug-
resistant TB in place of liquid culture and DST has limi-
tations. Each has suboptimal sensitivity in individuals
with smear-negative TB, and neither allows testing of
second line drugs; Xpert also does not allow assessment
of isoniazid mono-resistance [6,7]. To maximize detec-
tion of M. tuberculosis and drug-resistance, laborato-
ries may choose to perform conventional culture and
DST in addition to newer molecular assays. We
found that intensive implementation of molecular
testing in conjunction with conventional diagnostics
for all sputa in order to optimize both sensitivity
and speed of diagnosis would lead to significant
laboratory cost increases (70-120% increase), making
this option potentially unaffordable for laboratories in
some settings.
To assist laboratories in allocation of resources, we
examined the costs of multiple diagnostic algorithms.
Alternative diagnostic algorithms with selective applica-
tion of molecular assays may be considered in some
laboratories. We found that selectively performing Xpert
or MTBDRplus for smear-positive samples (while add-
itionally performing liquid culture and DST for all sam-
ples) leads to only modest increases in laboratory costs
(incremental $1.49 and $2.35 per sample for Xpert and
MTBDRplus, respectively). Such a strategy would allow
rapid species-level assessment of M. tuberculosis and
rapid identification of drug-resistant TB in those likely
to be most infectious, while also allowing performance
of reference standard testing on all patients. Similarly,
we found only relatively small increases to laboratory
costs if molecular testing were used as a rapid alternative
to conventional indirect phenotypic DST.
Table 3 Expected costs of diagnostic algorithms
Algorithm Cost per
sample
Incremental
cost
Implementation of conventional diagnostics versus molecular testing
Fluorescence microscopy plus liquid culture testing scenario* on all sputa $16.88 reference
Xpert MTB/RIF alone on all sputa $14.93 $-1.95
MTBDRplus alone on all sputa $23.46 $6.58
Intensive implementation of molecular tests in combination with conventional diagnostics
Xpert MTB/RIF plus liquid culture testing scenario* on all sputa $28.41 $11.53
MTBDRplus plus liquid culture testing scenario* on all sputa $36.94 $20.06
Conventional diagnostics with selective implementation of molecular tests
Fluorescence microscopy plus liquid culture testing scenario* on all sputa + Xpert MTB/RIF on smear-positive sputa $18.37 $1.49
Fluorescence microscopy plus liquid culture testing scenario* on all sputa + MTBDRplus on smear-positive sputa $19.23 $2.35
Fluorescence microscopy on all sputa plus a) Xpert MTB/RIF on smear-positive sputa and b) liquid culture on
smear-negative sputa with Xpert MTB/RIF on culture positive isolates
$16.51 -$0.37
Fluorescence microscopy on all sputa plus a) MTBDRplus on smear-positive sputa and b) liquid culture on smear-
negative sputa with MTBDRplus on culture positive isolates
$17.75 $0.87
Molecular testing with selective implementation of culture and dst**
Xpert MTB/RIF on all sputa, with liquid culture testing scenario* on sputa with a positive molecular test $16.86 $-0.02
MTBDRplus on all sputa, with liquid culture testing scenario* on sputa with a positive molecular test $25.39 $8.51
Abbreviations: MGIT Mycobacterial Growth Indicator 960 automated liquid culture system, DST Drug Susceptibility Testing using MGIT SIRE system.
* Liquid culture testing scenario consists of sputum processing and MGIT culture, followed by Ziehl Neelsen smear microscopy on positive cultures, anti-MPB64
assays on cultures with mycobacterial growth, and MGIT SIRE DST on cultures with growth of M. tuberculosis.
**Utilizes current estimates of Xpert and MTBDRplus sensitivity and specificity and prevalence of TB and drug-resistant TB in South Africa.
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Our study has several limitations. Not all countries
qualify for negotiated reduced pricing, and costs associ-
ated with labor (i.e. wages) and overhead can vary
geographically. Nonetheless we provide a detailed
cost-breakdown to aid generalizability and allow labora-
tories in other settings to estimate costs associated with
implementing these emerging rapid TB diagnostic tests
and provide cost estimates for Xpert testing without
negotiated prices. This study was a cost-analysis from a
reference laboratory perspective. Cost of transportation
to a reference laboratory were not included in this ana-
lysis and may represent a significant expense and vary
geographically; alternatively, implementation of Xpert at
a lower level of the health system may avert specimen
transport costs associated with mycobacterial culture
and conventional DST that must be performed in more
established laboratories. TB control programs making
decisions on diagnostic algorithms must additionally
consider costs associated with clinical evaluation and TB
treatment in addition to laboratory costs, as well as con-
sider the local prevalence of TB and drug-resistance and
the need for rapid diagnosis. Nevertheless, our study
provides important information regarding the likely
diagnostic costs associated with incorporating Xpert and
MTBDRplus as part of future diagnostic strategies.
On the other hand, our study has several strengths.
We incorporated recent negotiated price reductions
to aid generalizability to other low and middle-
income settings, and report the component of costs
attributable to consumables, equipment, and labor for
each TB diagnostic system. We found that the Xpert
and MTBDRplus laboratory costs are comparable to
those of conventional diagnostics and should be con-
sidered as part of TB diagnostic algorithms; we add-
itionally offer insight into the costs of alternative
algorithms that some laboratories may be considering.
Our results provide important information to aid fu-
ture studies evaluating cost-effectiveness and imple-
mentation of emerging TB diagnostic algorithms and
TB case-finding strategies.
Conclusions
The cost of newer molecular diagnostic tests are
comparable to conventional diagnostic methods, when
paying reduced negotiated pricing for Xpert and
MTBDRplus. We present detailed cost information re-
lated to implementation of these rapid molecular assays
to guide laboratories seeking to scale up TB diagnostics.
Overall, laboratories and TB programs must balance
costs with performance characteristics and the need for
rapid results. Intensive implementation of molecular as-
says as an addition to conventional automated liquid
culture and DST may lead to significant laboratory cost
increases; selective implementation of molecular assays
could be considered for some settings.
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